Access to Radioligand Therapy for Prostate Cancer in US Veterans
Official title: Access and Outcomes of Radioligand Therapy for US Veterans with Prostate Cancer
Funded at Sloan-Kettering Inst Can Research · NIH-11466088 · Data updated 2026-11-12
A study to understand how veterans with advanced prostate cancer access and experience radioligand therapy to guide better care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 6, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $708,377 |
| NIH project number | 1R01CA318433-01 |
| Project ID | NIH-11466088 on NIH RePORTER |
Who could benefit from this research
✓Could help
Veterans with advanced or castration-resistant prostate cancer who may be considered for radioligand therapy within or outside VA facilities.
✕Less likely to help
Patients who are not candidates for radioligand therapy or whose treatment is not influenced by access and system-level factors.
What this research studies
This project looks at how veterans with castration-resistant prostate cancer get radioligand therapy in the VA system, where uptake and logistics may limit access. It will examine where Lu-177 therapy is available, how patients move through the system, and what outcomes occur in real-world care. The goal is to identify barriers and opportunities to improve timely, effective treatment for veterans. Findings could inform policy and regional practice to ensure eligible patients can receive this targeted therapy.
Why it matters
Potential benefit: If successful, the work could lead to better access and outcomes for veterans with advanced prostate cancer who could benefit from radioligand therapy.
How similar studies have gone: Previous trials showed radioligand therapy can improve outcomes, but real-world access and effectiveness in veterans remain uncertain.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Mitchell, Aaron P — Sloan-Kettering Inst Can Research
- Study coordinator: Mitchell, Aaron P
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.